Mitochondrial cytopathy in adults: What we know so far

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 7, 2001, Pages 625-642

  Cohen, Bruce H ^a,b   Gold, Deborah R ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CARNITINE; CREATINE PHOSPHATE; FOLIC ACID ANTAGONIST; MITOCHONDRIAL DNA; NICOTINAMIDE; PREDNISONE; RIBOFLAVIN; SELENIUM; THIAMINE; THIOCTIC ACID; UBIDECARENONE;

ABDOMINAL CRAMP; ATAXIA; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DIAGNOSTIC TEST; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENCEPHALOMYOPATHY; ENDOCRINE DISEASE; GENE MUTATION; HEART DISEASE; HEREDITARY OPTIC ATROPHY; HUMAN; KEARNS SAYRE SYNDROME; KIDNEY DISEASE; LEIGH DISEASE; LIVER DISEASE; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MUSCLE BIOPSY; MYOCLONUS EPILEPSY; NEUROPATHY; PERCEPTION DEAFNESS; PTOSIS; RETINITIS PIGMENTOSA; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 0034935429     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.7.625     Document Type: Review

References (60)

1. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical and morphological study. J Clin Invest 1962; 41:1776-1804.
2. DiMauro S, Bonilla E. Mitochondrial encephalomyopathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, editors. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann, 1997:201-235.
3. Shoffner JM, Wallace DC. Oxidative phosphorylation diseases. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The metabolic and molecular bases of inherited disease New York: McGraw-Hill, 1995:1535-1610.
4. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 238:1482-1488.
5. Giles RE, Blanc H, Cann HM, Wallace DC. Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci USA 1980; 77:6715-6719
6. Shoffner JM. Mitochondrial myopathy diagnosis. Neurol Clin 2000; 18:105-123.
7. Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999; 341:1037-1044.
8. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997; 18:173-178.
9. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease Mutat Res 1992; 275:169-180.
10. Wallace DC. Mitochondrial DNA mutations and bioenergetic defects in aging and degenerative diseases. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, editors. The molecular and genetic basis of neurologic disease. Boston, Butterworth-Heinemann, 1997:237-269.
11. Melov S, Shoffner JM, Kaufman A, Wallace DC. Marked increase in the number and variety of mitochondrial DNA rearrangements in aging human skeletal muscle. Nucleic Acids Res 1995; 23:4122-4126.
12. Pavlakis SG, Phillips PC, DiMauro S, DeVivo DC, Rowland LP. Mitochondrial myopathy, encephalomyopathy, lactic acidosis and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16:481-488.
13. Goto Y, Nonaka I, Horai S. A mutation in the tRNALeu(URR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348 653.
14. Bardosi A, Creutzfeldt W, DiMauro S, et al. Myo-, neuro-, gastrointestinal encephalomyopathy (MNGIE syndrome) due to partial deficiency of cytochrome c oxidase: a new mitochondrial multisystem disorder. Acta Neuropathol (Berl) 1987; 74:248-158.
15. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrtal disorder. Science 1999, 283.689-692.
16. Lietman PS. Mitochondrial protein synthesis: inhibition by emetine hydrochloride Mol Pharmacol 1971; 7:122-128.
17. Huang CC, Chu CC Pang CY, Wei YH. Tissue mosaicism in the skeletal muscle and sural nerve biopsies in the MELAS syndrome. Acta Neurol Scand 1999; 99 125-129.
18. Peyronnard JM, Charron L, Bellavance A, Marchand L. Neuropathy and mitochondrial myopathy. Ann Neurol 1980; 7:262-268.
19. Kenny D, Wetherbee J. Kearns-Sayre syndrome in the elderly: mitochondrial myopathy with advanced heart block. Am Heart J 1990; 120:440-443.
20. Mashima Y, Kigasawa K, Hasegawa H, Tani M, Oguchi Y. High incidence of pre-excitation syndrome in Japanese families with Leber's hereditary optic neuropathy. Clin Genet 1996; 50:535-537.
21. Kerrison JB, Biousse V, Newman NJ. Retinopathy of NARP syndrome. Arch Ophthalmol 2000, 118.298-299.
22. Smith PR, Bain SC, Good PA, et al. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness cause by the mitochondrial DNA 3243 tRNA (Leu) A to G mutation. Ophthalmology 1999; 106.1101-1108.
23. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242:1427-1430.
24. Chalmers RM, Schapira AH, Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy. Biochim Biophys Acta 1999; 1410:147-158
25. Fischel-Ghodsian N. Mitochondrial genetics and hearing loss: the missing link between genotype and phenotype. Proc Soc Exp Biol Med 1998; 218:1-6.
26. Jacobs HT. Mitochondrial deafness. Ann Med 1997; 29:483-491.
27. Niaudet P. Mitochondrial disorders and the kidney. Arch Dis Child 1998; 78.387-390.
28. Niaudet P, Rotig A. The kidney in mitochondrial cytopathies. Kidney Int 1997; 51:1000-1007.
29. Odawara M. Involvement of mitochondrial gene abnormalities in the pathogenesis of diabetes mellitus. Ann NY Acad Sci 1996; 786:72-81.
30. Gerbitz KD, van den Ouweland JM, Maassen JA, Jaksch M. Mitochondrial diabetes mellitus: a review. Biochim Biophys Acta 1995; 1271:253-260.
31. van den Ouweland JM, Lemkes HH, Trembath RC, et al. Maternally inherited diabetes and deafness is a distinct subtype of diabetes and associates with a single point mutation in the mitochondrial tRNA (Leu(URR)) gene Diabetes 1994; 43:746-751.
32. Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995; 32:132-138.
33. Kuratsune H, Yamaguti K, Takahashi M, Tagawa S, Kitani T. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 1994; 18(suppl 1):62-67
34. Griggs RC, Karpati G. Muscle pain, fatigue, and mitochondriopathies. N Engl J Med 1999, 341:1077-1078.
35. Walker UA, Collins S, Byrne E. Respiratory chain encephalomyopathies: a diagnostic classification. Eur Neurol 1996; 36:260-267.
36. Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987; 234:62-63.
37. Ogasahara S, Yorifuji S, Nishikawa Y, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985; 35.372-377.
38. Bresolin N, Bet L, Binda A, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988; 38:892-899.
39. Abe K, Fujimura H, Nishikawa Y, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991; 83:356-359.
40. Gold R, Seibel P, Reinelt G, et al. Phosphorous magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies; Results of a 6-month therapy study with coenzyme Q. Eur Neurol 1996; 36:191-196.
41. Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. BioFactors 1999; 9:253-260.
42. Bendahan D, Desnuelle C, Vanuxem D, et al. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992; 42:1203-1209.
43. Bresolin N, Doriguzzi C, Ponzetto C et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990; 100:70-78.
44. Zierz S, von Wersebe O, Bleistein J, Jerusalem F. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci 1990; 95:283-290.
45. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993; 43:884-890.
46. Pons R, DeVivo DC. Primary and secondary carnitine deficiency syndrome. J Child Neurol 1995; 10(suppl 2):8-24.
47. Campos Y, Huertas R, Lorenzo G, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993; 16:150-153.
48. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation Clin Sci 1992; 83:367-374.
49. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20:1502-1509.
50. Tarnopolsky MA, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52:854-857.
51. Naito E, Ito M, Yokota I, et al. Concomitant administration of sodium dichloroacetate and thiamine in West syndrome caused by thiamine-responsive pyruvate dehydrogenase complex deficiency. J Neurol Sci 1999; 171:56-59.
52. DiRocco M, Lamba LD, Minniti G, Caruso U, Naito E. Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. Eur J Paediatr Neurol 2000; 4.115-117.
53. Gregersen N. Riboflavin-responsive defects of beta-oxidation J Inherit Metab Dis 1985; 8(suppl 1):65-69.
54. Wolf B, Heard GS, Jefferson LG, Proud VK, Nance WE, Weissbecker KA. Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program. N Engl J Med 1985; 313:16-19.
55. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin i migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466-470.
56. Yee AJ. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology 1999; 52:431-432.
57. Mattimoe D, Newton W. High-dose riboflavin for migraine prophylaxis. Fam Pract 1998; 47:11.
58. Sastre J, Pallardo FV, Garcia de la Asuncion J, Vina J. Mitochondria, oxidative stress and aging. Free Radic Res 2000; 32:189-198
59. Mecocci P, MacGarvey U, Kaufman AE, et al. Oxidative damage to mito chondrial DNA shows marked age-dependent increases in human brain Ann Neurol 1993; 34:609-616.
60. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness? Ann Neurol 1992; 31:119-130.